{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T21:30:33Z","timestamp":1776893433003,"version":"3.51.2"},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jval.2016.11.001","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T11:42:14Z","timestamp":1483616534000},"page":"618-626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Development of the Diary for Irritable Bowel Syndrome Symptoms to Assess Treatment Benefit in Clinical Trials: Foundational Qualitative Research"],"prefix":"10.1016","volume":"20","author":[{"given":"Sheri E.","family":"Fehnel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire M.","family":"Ervin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn T.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianna","family":"Rigoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Lackner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen Joel","family":"Coons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2016.11.001_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/clpt.2011.203","article-title":"The Patient-Reported Outcome (PRO) Consortium: filling measurement gaps for PRO endpoints to support labeling claims","volume":"90","author":"Coons","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jval.2016.11.001_bib2","unstructured":"Food and Drug Administration. Guidance for industry and FDA staff: qualification process for drug development tools. January 2014. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM230597.pdf. [Accessed February 2, 2016]."},{"key":"10.1016\/j.jval.2016.11.001_bib3","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMcp0801447","article-title":"Clinical practice. Irritable bowel syndrome","volume":"358","author":"Mayer","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2016.11.001_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1574887111308010003","article-title":"Clinical trials in irritable bowel syndrome: a review","volume":"8","author":"Ervin","year":"2013","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.jval.2016.11.001_bib5","unstructured":"Food and Drug Administration. Guidance for industry\u2014patient-reported outcome measures: use in medical product development to support labeling claims. December 2009. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf. [Accessed February 2, 2016]."},{"key":"10.1016\/j.jval.2016.11.001_bib6","unstructured":"Food and Drug Administration. Irritable bowel syndrome\u2014clinical evaluation of products for treatment. March 2012. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM205269.pdf. [Accessed February 2, 2016]."},{"key":"10.1016\/j.jval.2016.11.001_bib7","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1053\/j.gastro.2006.03.008","article-title":"The functional gastrointestinal disorders and the Rome III process","volume":"130","author":"Drossman","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jval.2016.11.001_bib8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1023\/A:1018831127942","article-title":"Quality of life in persons with irritable bowel syndrome: development and validation of a new measure","volume":"43","author":"Patrick","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jval.2016.11.001_bib9","first-page":"521","article-title":"The patient\u2019s perspective of irritable bowel syndrome","volume":"50","author":"Bertram","year":"2001","journal-title":"J Fam Pract"},{"key":"10.1016\/j.jval.2016.11.001_bib10","year":"2002","journal-title":"IBS in the real world survey: summary findings"},{"key":"10.1016\/j.jval.2016.11.001_bib11","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/ajg.2014.241","article-title":"Fear of GI symptoms has an important impact on quality of life in patients with moderate-to-severe IBS","volume":"109","author":"Lackner","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jval.2016.11.001_bib12","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1001\/archinte.164.16.1773","article-title":"Clinical determinants of health-related quality of life in patients with irritable bowel syndrome","volume":"164","author":"Spiegel","year":"2014","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jval.2016.11.001_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00004836-199407000-00008","article-title":"An office guide to whole-gut transit time\u2014patients\u2019 recollection of their stool form","volume":"19","author":"Heaton","year":"1994","journal-title":"J Clin Gastroenterol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301516340712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301516340712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:24:46Z","timestamp":1761056686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301516340712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1098301516340712"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2016.11.001","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of the Diary for Irritable Bowel Syndrome Symptoms to Assess Treatment Benefit in Clinical Trials: Foundational Qualitative Research","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}